Document:

Exhibit

Exhibit 10.1

NewLink Genetics Corporation
 
Lock-Up Agreement
 
[•], 2019
 
This Lock-Up Agreement (this “Agreement”) is executed in connection with the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) by and among NewLink Genetics Corporation (the “Parent”), Cyclone Merger Sub, Inc., (“Merger Sub”), and Lumos Pharma, Inc. (the “Company”), dated as of [•], 2019. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Merger Agreement.
 
In connection with, and as an inducement to, the parties entering into the Merger Agreement and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned, by executing this Agreement, agrees that, without the prior written consent of the Parent, during the period commencing at the Effective Time and continuing until the end of the Lock-Up Period (as hereinafter defined), the undersigned will not: (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of or lend, directly or indirectly, any shares of Common Stock of Parent (the “Parent Common Stock”) or any securities convertible into, exercisable or exchangeable for or that represent the right to receive Parent Common Stock (including without limitation, Parent Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) whether now owned or hereafter acquired (the “Securities”); (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Parent Common Stock or such other securities, in cash or otherwise; (3) grant any proxies or powers of attorney with respect to any Securities, deposit any Securities into a voting trust or enter into a voting agreement or similar arrangement or commitment with respect to any Securities, other than the grant of any proxies to any officer of Parent in connection with the Parent Stockholders’ Meeting or (4) publicly disclose the intention to do any of the foregoing (each of the foregoing restrictions, the “Lock-Up Restrictions”).
 
The Lock-Up Restrictions shall automatically terminate and cease to be effective on the date that is one-hundred and eighty (180) days after the Effective Time. The period during which the Lock-Up Restrictions apply to the Securities shall be deemed the “Lock-Up Period” with respect thereto.
 
The undersigned agrees that the Lock-Up Restrictions preclude the undersigned from engaging in any hedging or other transaction with respect to any then-subject Securities which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of such Securities even if such Securities would be disposed of by someone other than the undersigned.  Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to such Securities or with respect to any security that includes, relates to, or derives any significant part of its value from such Securities.
 
Notwithstanding the foregoing, the undersigned may transfer any of the Securities (i) as a bona fide gift or gifts or charitable contribution(s), (ii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, (iii) if the undersigned is a corporation, partnership, limited liability 

Exhibit 10.1

company, trust or other business entity (1) to another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule 405 promulgated under the Securities Act) of the undersigned or (2) as distributions of shares of Parent Common Stock or any security convertible into or exercisable for Parent Common Stock to limited partners, limited liability company members or stockholders of the undersigned or holders of similar equity interests in the undersigned, (iv) if the undersigned is a trust, to the beneficiary of such trust, (v) by testate succession or intestate succession, (vi) to any immediate family member, any investment fund, family partnership, family limited liability company or other entity controlled or managed by the undersigned, (vii) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (vi), (viii) to Parent in a transaction exempt from Section 16(b) of the Exchange Act upon a vesting event of the Securities or upon the exercise of options or warrants to purchase Parent Common Stock on a “cashless” or “net exercise” basis or to cover tax withholding obligations of the undersigned in connection with such vesting or exercise (but for the avoidance of doubt, excluding all manners of exercise that would involve a sale in the open market of any securities relating to such options or warrants, whether to cover the applicable aggregate exercise price, withholding tax obligations or otherwise), (ix) to Parent in connection with the termination of employment or other termination of a service provider and pursuant to agreements in effect as of the Effective Time whereby Parent has the option to repurchase such shares or securities, (x) acquired by the undersigned in open market transactions after the Effective Time, (xi) pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Parent’s capital stock involving a Change of Control of the Parent, provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Securities shall remain subject to the restrictions contained in this Agreement, or (xii) pursuant to an order of a court or regulatory agency; provided, in the case of clauses (i)-(vii), that (A) such transfer shall not involve a disposition for value and (B) the transferee agrees in writing with Parent to be bound by the terms of this Agreement.  For purposes of this Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin and “Change of Control” shall mean the consummation of any bona fide third party tender offer, merger, consolidation or other similar transaction the result of which is that any “person” (as defined in Section 13(d)(3) of the Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of more than 50% of total voting power of the voting stock of the Parent; provided that, for the avoidance of doubt, the consummation of the Contemplated Transactions shall not constitute a Change of Control for purposes of this Agreement. 
 
In addition, the foregoing restrictions shall not apply to (i) the exercise of stock options (x) that would expire during the Lock-Up Period or (y) other than Company Options that are converted into and become options to purchase Parent Common Stock pursuant to Section 5.4(a) of the Merger Agreement, that are granted pursuant to Parent Stock Plans existing following the Effective Time, including in each case the “net” exercise of such options in accordance with their terms and the surrender of Parent Common Stock in lieu of payment in cash of the exercise price and any tax withholding obligations due as a result of such exercise; provided that it shall apply to any of the Securities issued upon such exercise, or (ii) the establishment of any contract, instruction or plan (a “Plan”) that satisfies all of the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act; provided that no sales of the Securities shall be made pursuant to such a Plan prior to the expiration of the Lock-Up Period, and such a Plan may only be established if no public announcement of the establishment or existence thereof and no filing with the Securities and Exchange Commission or other regulatory authority in respect thereof or transactions thereunder or contemplated thereby, by the undersigned, Parent or any other person, shall be required, and no such announcement or filing is made voluntarily, by the undersigned, Parent or any other person, prior to the expiration of the applicable Lock-Up Period.  In furtherance of the foregoing, Parent and its transfer agent and registrar are hereby authorized to decline to make any transfer of shares of Parent Common Stock if such transfer would constitute a violation or breach of this Agreement.

Exhibit 10.1

The undersigned understands that the Securities shall bear the following or substantially similar legends, whether in book-entry or certificated form (in addition to any other legends required by law or any agreement to which any such Seller is a party):    
“THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO AN AGREEMENT BY THE REGISTERED HOLDER HEREOF THAT RESTRICTS THE TRANSFER OR SALE OF THESE SHARES BEFORE THE DATE THAT IS 180-DAYS AFTER THE EFFECTIVE TIME. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST OF THE SECRETARY OF THE ISSUER”
The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement and that upon request, the undersigned will execute any additional documents reasonably necessary to ensure the validity or enforcement of this Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. 
The undersigned understands that the undersigned shall be released from all obligations under this Agreement if the Merger Agreement is terminated prior to the Effective Time pursuant to its terms, upon the date of such termination. 
In the event that, during the Lock-Up Period, the Parent releases or waives any prohibition set forth in this Lock-Up Agreement on the transfer of Securities held by any of the stockholders of the Parent or the Company or any of their respective affiliates who receive shares from one or more of such stockholders during the Lock-Up Period as permitted by this Lock-Up Agreement, the same percentage of the total number of Securities held by the undersigned as the percentage of the total number of outstanding Securities held by such stockholder that are the subject of such waiver shall be immediately and fully released on the same terms from the applicable prohibition(s) set forth herein. Notwithstanding the foregoing, the provisions of this paragraph will not apply if (1) the release or waiver is effected solely to permit a transfer not involving a disposition for value and (2) the transferee agrees in writing to be bound by the same terms described in this Lock-Up Agreement to the extent and for the duration that such terms remain in effect at the time of transfer.  The Parent shall use commercially reasonable efforts to promptly notify the undersigned of each such release (provided that the failure to provide such notice shall not give rise to any claim or liability against the Parent or the Company). 
The undersigned understands that Parent, the Merger Sub and the Company are entering into the Merger Agreement in reliance upon this Agreement. 
This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware.

[Signature Page Follows]

Exhibit 10.1

This Agreement, and any certificates, documents, instruments and writings that are delivered pursuant hereto, constitutes the entire agreement and understanding of the Parent, the Company and the undersigned in respect of the subject matter hereof and supersedes all prior understandings, agreements or representations by or among the Parent, the Company and the undersigned, written or oral, to the extent they relate in any way to the subject matter hereof.
 

	
		
	 
	Very truly yours,

  
	
				
	 
	 
	 

	 
	 

	 
	 
	Printed Name of Holder

	 
	 
	 

	 
	By:
	 

	 
	 
	Signature

	 
	 
	 

	 
	 
	 

	 
	 
	Printed Name of Person Signing

	 
	(and indicate capacity of person signing if

	 
	signing as custodian, trustee, or on behalf of an entity)Exhibit

Exhibit 10.2

September 27, 2019 
Nicholas Vahanian, M.D.
1723 Glenleven Terrace
West Des Moines, IA 50266
Re:    Transition Agreement
Dear Nick:
This letter sets forth the terms of the transition agreement (the “Transition Agreement” or the “Agreement”) that NewLink Genetics Corporation (the “Company”) is offering to aid in your employment transition.
1.Transition Period and Separation Date.  You hereby resign as President of the Company, and from any other office or position you may hold with the Company and any affiliated entities, including your position on the Board of Directors of the Company and any affiliated entities, effective as of September 27, 2019 (the “Resignation Date”).  The period from such date through the date your employment terminates (the “Separation Date” as described below) is your “Transition Period.” During the Transition Period you will remain an employee of the Company.  You have qualified for Short Term Disability (“STD”) benefits under the Company’s STD Plan for eight weeks beginning August 17, 2019, and are awaiting a decision on extension of such benefits.  The Separation Date will be the date on which your STD benefits terminate (but in no event later than November 8, 2019).  From the date hereof through the Separation Date, you will be paid at 75% of your regular salary.  On the Company’s next regular payroll date following the Separation Date, the Company will pay you all accrued base salary and all remaining accrued but unused vacation earned for your services through the Separation Date, less applicable payroll deductions and withholdings (the “Accrued Obligations”).  You will receive the Accrued Obligations regardless of whether or not you sign this Agreement.
2.    Expense Reimbursements.  You agree that, within thirty (30) days of the Separation Date, you will submit to the Company your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement.  The Company will reimburse you for these expenses pursuant to its regular business practice.
3.    Severance Benefits.  Under the circumstances of your separation from the Company you are not eligible for any severance benefits set forth in your Employment Agreement with the Company dated January 4, 2016 (the “Employment Agreement”) or otherwise.  If you execute this Transition Agreement and execute and do not revoke the Release Agreement attached as Exhibit A (the “Release Agreement”), in each case within the specified time period, and comply with your obligations thereunder, the Company shall provide you with the severance payments and benefits 

-1-

(collectively, the “Severance Benefits”) described below.  Except as expressly provided otherwise, all cash benefits shall be paid subject to applicable payroll deductions and withholdings.
(a)    Cash Severance.  
(i)    2019 Bonus.  The Company also will pay you a bonus for your 2019 services (the “Bonus Payment”) equal to $133,877, calculated as follows: $180,915 (representing the actual 2018 Bonus paid) multiplied by .740 (representing a prorated portion (270/365 days) for the period of employment in 2019).  The Bonus Payment will be paid to you no later than the time 2019 bonuses are paid to other executives, and in any event not later than March 15, 2020.
(ii)    Continuation Payments.  Consistent with the severance provisions set forth in Sections 9(g) and 11 of your Employment Agreement, the Company will pay you cash severance equal to $861,450, representing the base salary provided in your Employment Agreement, for a period of eighteen (18) months (the “Salary Continuation Payment”).  As required by Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”), the Salary Continuation Payment shall be paid in a lump sum upon the first regularly scheduled payroll date that is six (6) months after the Separation Date, provided the Company has received the executed Agreement from you on or before that date.  No interest will be paid to you on any amounts for which payment is delayed pursuant to the foregoing provision
(b)    Healthcare Continuation Coverage Payments; other HealthCare Allowance.
(i)    COBRA Election.  To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company’s current group health insurance policies, you may be eligible to continue your group health insurance benefits at your own expense after the Separation Date.
(ii)    COBRA Premiums.  As an additional severance benefit, if you timely elect continued coverage under COBRA, and execute, return and do not revoke this Agreement, the Company will pay that portion of your premiums that it was paying prior to the Separation Date for your basic medical coverage (including coverage for any eligible dependents, if applicable, but excluding dental and vision insurance coverage) (the “COBRA Premiums”) for the period (the “COBRA Premium Period”) starting on the Separation Date and ending on the earliest to occur of: (i) eighteen (18) months after the Separation Date; (ii) the date you become eligible for group health insurance coverage through a new employer; or (iii) the date you cease to be eligible for COBRA continuation coverage for any reason, including plan termination.  In the event you become covered under another employer’s group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you shall immediately provide written notification of such event to the Company’s Human Resources Manager.  
(iii)    Alternative Cash Payments in Lieu of COBRA Premiums.  Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without a substantial risk of violating applicable law (including but not 

-2-
 

limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), the Company instead shall pay you, on the first day of each calendar month following such determination, a fully taxable cash payment which, after taxes, is equal to the COBRA Premium amount the Company would have otherwise paid you for that month (assuming a 35% tax rate) (such amount, the “Alternative Cash Payment”), for the remainder of the COBRA Premium Period.  You may, but are not obligated to, use such Alternative Cash Payments toward the cost of COBRA premiums.
(iv)    Allowance for Medical and Rehabilitation Costs.  As an additional benefit to you, the Company will pay you a fully taxable cash payment of $400,000 within 30 days after the Separation Date as an allowance for future medical costs, healthcare insurance, and rehabilitation expenses.
(c)    Equity.  You have been granted options to purchase shares of the Company’s common stock (the “Options”) and certain restricted stock units (the “RSUs,” and together with the Options, the “Awards”) pursuant to the Company’s 2009 Equity Incentive Plan (the “Plan”).  Vesting of any unvested Awards would cease on the Separation Date.  As an additional severance benefit, the Company will (i) accelerate the vesting of the outstanding and unvested Awards set forth on Exhibit B (the “Subject Awards”) so that you are credited with an additional twelve (12) months of vesting as of such date (the “Accelerated Vesting”); and (ii) extend the exercise period under the governing agreements and Plan documents so that you have two (2) years from the Separation Date to exercise the shares vested as of the Separation Date (the “Extended Exercise Period”).  To the extent that any performance criteria under any Award have not been satisfied as of the Separation Date, such Awards shall terminate as of the Separation Date.  Except as expressly provided in this Section, the Options and RSUs will continue to be governed by the terms of the governing agreements and Plan documents.  You acknowledge and agree that the Extended Exercise Period may convert any portion of the Options that were incentive stock options into non-qualified stock options, thereby changing their tax treatment; and you should seek advice from your own tax advisors about this extension.
(d)    Priority Review Voucher.  If the Company receives the Current Product Voucher contemplated by section 5.3.1 of the License and Collaboration Agreement between Merck Sharpe & Dohme Corp. (“Merck”), Bioprotection Systems Corporation, and the Company, dated November 21, 2018, as amended and as the same may be amended from time to time,  then the Company shall pay you (or a charity designated by you) an amount equal to one half of one percent (0.5%) of the net amount actually received by the Company (in the event of a sale of such voucher), or the portion of the Current Product Voucher Value retained by the Company (if such voucher is retained by the Company),  in each case after deducting all amounts paid or payable by the Company to Merck, Public Health Canada (as defined therein), or any other third parties entitled to a share of such amounts, and after deducting any fees or costs incurred in obtaining or selling such voucher.  The foregoing right shall expire if such voucher has not been issued to the Company by December 31, 2024.
(e)    409A Compliance.  It is intended that the Severance Benefits provided to you hereunder comply with, or be exempt from, Section 409A, and that any ambiguities herein will 

-3-
 

be interpreted to so comply and/or be exempt from Section 409A.  It is intended that all of the benefits and payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulations Sections 1.409A‐1(b)(4), 1.409A‐1(b)(5) and 1.409A‐1(b)(9), and this Agreement will be interpreted accordingly.  To the extent not so exempt, this Agreement (and any definitions hereunder) will be interpreted in a manner that complies with the Section 409A requirements.  For purposes of Section 409A, your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.  If the period of time you could sign this Agreement crosses over two calendar years, the Agreement shall be deemed to have become effective on the last possible date it could become effective.
(f)    280G Compliance.  Section 12 of the Employment Agreement is incorporated herein.
4.    Benefits.  Your participation in Employer-Sponsored Group Life Insurance and Short and Long Term Disability Insurance will cease as of the Separation Date; however, you may elect to convert your Life Insurance by contacting Mutual of Omaha at (800) 228-7104 or refer to the conversion notice attached hereto.  Termination of your participation will not affect your eligibility for benefits for which you qualified during employment and for which you remain eligible after the Separation Date.
(a)    Deductions for the 401(k) Plan will end with your last regular paycheck.  You will receive information by mail concerning 401(k) plan rollover procedures should you be a participant in this program.
(b)    You have the right to continue your current Health Care Spending Account if you are participating in this program.  Information on how to continue this benefit will be mailed to you by Discovery Benefits along with your COBRA details.  Dependent Care Spending Accounts cannot be continued.  Your last full Spending Account payroll deductions will be processed on your final paycheck.  Unless you elect to continue your Health Care Spending Account, you will only be eligible to claim expenses that you incurred through the end of the month of your separation date.
5.    Other Compensation or Benefits.  You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive after the Separation Date any additional compensation, severance or benefits, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account).  By way of example, you acknowledge that you have not earned and are not owed any bonus, incentive compensation, commissions or equity (other than as provided or referenced herein) from the Company.  
6.    Return of Company Property.  No later than the close of business on the Separation Date, you shall return to the Company all Company non-public documents (and all copies thereof) and other Company property or information in your possession or control (collectively, “Company 

-4-
 

Property”), including, but not limited to: Company hardcopy and softcopy files, databases, notes, emails, correspondence, financial and operational information, current or potential customer lists and contact information, product and services information, research and development information, drawings, records, plans, forecasts, reports, payroll information, spreadsheets, studies, analyses, compilations of data, proposals, agreements, sales and marketing information, personnel information, specifications, code, software, electronically or computer-recorded information, tangible property and equipment (including, but not limited to, computing and communications devices, facsimile machines, mobile telephones, servers), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain or embody any proprietary or confidential information of the Company and all reproductions thereof in whole or in part and in any medium, except that you shall be permitted to retain your Company-issued cell phone, desktop computer, laptop and printer, provided you shall comply with the penultimate  sentence of this Section 6 with respect to such cell phone and laptop.  You shall make a diligent search to locate any such Company Property by the close of business on the Separation Date.  In addition, if you have used any personally owned computing or communication device, server, or e-mail system to receive, store, review, prepare or transmit any confidential or proprietary data, materials or information of the Company, then within five (5) business days after the Separation Date, you shall permanently delete and expunge such confidential or proprietary information from those systems without retaining any reproductions (in whole or in part); and you agree to make any such device or system available for inspection and analysis by the Company, upon its reasonable request, in order to permit the Company to determine whether you are in compliance with this provision.  Your timely compliance with the provisions of this Section is a precondition to your receipt of the Severance Benefits and other benefits provided hereunder.
7.    Proprietary Information, Non-Solicitation and Non-Competition Obligations.  You acknowledge and agree to abide by your continuing obligations under your Employee Proprietary Information, Inventions, Non-Competition, and Non-Solicitation Agreement with the Company (the “Proprietary Information Agreement” described in  Exhibit C), effective as of the beginning of your employment with the Company and continuing after the Separation Date, including but not limited to your obligations not to use or disclose any confidential or proprietary information of the Company and to refrain from certain solicitation and competitive activities.  Confidential information that is also a “trade secret,” as defined by law, may be disclosed (A) if it is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  In addition, in the event that you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney and use the trade secret information in the court proceeding, if you: (A) file any document containing the trade secret under seal; and (B) do not disclose the trade secret, except pursuant to court order.
8.    Non-Disparagement.  Both you and the Company agree not to disparage the other party, and the other party’s officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that both you and the Company will respond accurately and fully to any question, inquiry or request 

-5-
 

for information when required by legal process.  The Company’s obligations under this Section are limited to the Company’s directors, officers and other Company representatives with knowledge of this provision.  Notwithstanding the foregoing, nothing in this Agreement shall limit your right to voluntarily communicate with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, other federal government agency or similar state or local agency or to discuss the terms and conditions of your employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act.   
9.    Public Statements.  Both the Company and you shall respond to third party inquiries, and the Company shall issue a press release, effectively stating that you have resigned from your position as President as of the Resignation Date.
10.    References.  In response to any request for references from a prospective employer, the Company will verify only your last job title and dates of employment.
11.    Cooperation.
(a)    Transition Briefings.  Prior to and after the Separation Date, you agree to cooperate fully with the Company in all matters relating to the transition of your work and responsibilities on behalf of the Company, including, but not limited to, transitioning any work relationships and providing oral and written briefings (as requested) with respect to any past or present work activities and institutional knowledge, to such other persons as may be designated by the Company.  You agree to make yourself available to respond to such inquiries with reasonable promptness, either telephonically or by email (as requested), unless the Company requests that you come to the Company at reasonably convenient times for such discussion or to review certain documents or materials related to the inquiry.
(b)    No Voluntary Adverse Assistance.  You agree that you will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any third party (including both persons and entities) in connection with any claim or cause of action of any kind brought against, or being prepared against, the Company by any third party, nor shall you induce or encourage any person or entity to bring such claims; provided, however, that nothing herein shall limit or restrict your right to engage in any of the protected activities described in Section 14 (Protected Rights) below.
(c)    Other Voluntary Cooperation.  You agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during your employment with the Company.  Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony.  The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding forgone wages, salary, or other compensation), and will make reasonable efforts to accommodate your scheduling needs.  In 

-6-
 

addition, you agree to execute all documents (if any) necessary to carry out the terms of this Agreement.
12.    No Admissions.  Nothing contained in this Agreement shall be construed as an admission by you or the Company of any liability, obligation, wrongdoing or violation of law.
13.    Release of Claims.  In exchange for the Severance Benefits, including the Salary Continuation Payments, the reimbursement of your COBRA Premiums (or Alternative Cash Payments), the Accelerated Vesting,  and all other consideration provided to you by the Company under this Agreement that you would not otherwise be entitled to receive (the “Release Consideration”), you agree to the terms below.
(a)    General Release.  You hereby generally and completely release the Company and its parent or subsidiary entities, successors, predecessors and affiliates, and its and their directors, officers, employees, consultants, shareholders, agents, attorneys, insurers, affiliates and assigns (collectively, the “Released Parties”) of and from any and all claims, liabilities and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”).
(b)    Scope of Release.  The Released Claims include, but are not limited to: (1) all claims arising from or in any way related to your employment with the Company, or the termination of that employment; (2) all claims related to your compensation or benefits from the Company (except as expressly provided in this Agreement), including but not limited to salary, bonuses, commissions, vacation pay, PTO, expense reimbursement, severance pay, fringe benefits, profit sharing, stock, stock options, or any other ownership or equity interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing, including but not limited to any claims arising under or based on your initial employment offer letter or subsequent Employment Agreement (including claims for severance benefits thereunder); (4) all tort claims, including but not limited to claims for battery, negligence, fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims in all jurisdictions, including but not limited to claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964, the federal Americans with Disabilities Act of 1990, the federal Family and Medical Leave Act, the Equal Pay Act of 1963, the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act (and all similar state and local laws), the Iowa Civil Rights Act of 1965, the Iowa Wage Payment Collection Law, the Texas Commission on Human Rights Act, the Texas Payday Law, the Texas Labor Code, and any statute or regulation administered by the Texas Workforce Commission.
(c)    Excluded Claims.  Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”):  (1) rights to apply for unemployment insurance benefits; (2) rights to workers’ compensation disability benefits, claims and payments, if applicable; (3) any rights or claims for indemnification pursuant to any written indemnification agreement with the Company to which you are a party, or under Company bylaws or articles, or under applicable law; (4) any rights which cannot be waived as a matter of law; or (5) any claims for breach of this Agreement.  You represent and warrant that, other than the Excluded Claims, you 

-7-
 

are not aware of any claims you have or may have against any of the Released Parties that are not included in the Released Claims.  
14.    Protected Rights.  Nothing in this Agreement shall prevent you from challenging the validity of the release of claims provided herein in a legal or administrative proceeding.  You further understand that nothing in this Agreement (including, without limitation, , Section 8 (Non-Disparagement) and Section 13 (Releases of Claims) above): limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”); prevents any party from providing information or disclosing the fact or terms of this Agreement as part of any government investigation: or prohibits any party from reporting possible violations of law or regulation to any Government Agencies or self-regulating entity under applicable law (including, but not limited to, the U.S. Securities and Exchange Commission’s Whistleblower Rule, of Section 21F of the U.S. Securities Exchange Act of 1934, as amended).  While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to the maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any of the Released Claims and any rights you have waived by signing this Agreement.  
15.    Representations.  You hereby represent that, except for amounts to be paid to you under this Agreement, you have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which you have not already filed a claim.  You also represent and affirm that all of the decisions of the Released Parties regarding your pay and benefits through the date of your execution of this Agreement were not discriminatory based on age, disability, race, color, sex, religion, national origin or any other classification protected by law.  You further affirm that you have not filed, caused to be filed, and are not presently a party to a claim or cause of action against any of the Released Parties.  The Company represents that this agreement has been approved by all necessary corporate action and that the Company has the requisite authority to perform its obligations hereunder.   
16.    Breach.  You agree that upon a material breach of this Agreement you will forfeit all amounts paid or owing to you under Section 3(d) of this Agreement.  The Company shall also have all other remedies at law or in equity.  The parties acknowledge that it may be difficult to assess the damages caused by a violation of the terms of Sections 6, 7 and 8 of this Agreement and further agree that any threatened or actual violation or breach of those Sections of this Agreement will constitute immediate and irreparable injury to the non-breaching party.  Therefore, the parties agree that any such breach of this Agreement is a material breach of this Agreement, and, in addition to any and all other damages and remedies available, the non-breaching party shall be entitled to an injunction to prevent violation or breach of this Agreement.  The parties agree that if a party is successful in whole or part in any legal or equitable action under this Agreement, that party may recover all of the costs, including reasonable attorneys’ fees, incurred in enforcing the terms of this Agreement.  

-8-
 

17.    General.  This Agreement, including Exhibits A,  B and C, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to this subject matter, except as expressly provided herein.  It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other agreements, promises, warranties or representations concerning its subject matter (including but not limited to your Employment Agreement with the Company, except as expressly provided herein).  This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.  This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.  If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties.  This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Iowa as applied to contracts made and to be performed entirely within Iowa.  The parties hereby consent to the sole and exclusive jurisdiction of the state or federal court for Des Moines, Iowa for any actions, suits or proceedings arising out of or relating to this Agreement.  Any ambiguity in this Agreement shall not be construed against either party as the drafter.  Any waiver of a breach of this Agreement, or rights hereunder, must be in writing to be effective and shall not be deemed to be a waiver of any successive or other breach or rights hereunder.  This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile, .PDF and electronic signatures shall be equivalent to original signatures.  
Please sign and date this Agreement and return the fully executed Agreement to the Company by September 27, 2019.  In addition, the Severance Benefits are subject to your execution and non-revocation of the Release Agreement attached as Exhibit A.
We wish you the best in your future endeavors.

Sincerely,
NEWLINK GENETICS CORPORATION
By: /s/ Bradley Powers    
Bradley Powers
Office of the CEO and General Counsel

Exhibit A –Release Agreement
Exhibit B –Options and RSUs Subject to Twelve-Month Acceleration and Extended Exercise Period for Options

-9-
 

Exhibit C – Proprietary Information Agreement

UNDERSTOOD AND AGREED:
/s/ Nicholas Vahanian, M.D.    
Nicholas Vahanian, M.D.
9/27/2019    
Date

-10-
 

Exhibit 10.2

EXHIBIT A
RELEASE AGREEMENT
This Release Agreement (the “Release” or “Agreement”) is made by and between Nicholas Vahanian (“you”) and NewLink Genetics Corporation (the “Company”).  This Release was attached to and made part of the Transition Agreement letter to you dated September 27, 2019 (the “Transition Agreement”).
1.    Release of Claims.  In consideration for the Severance Benefits, including the Salary Continuation Payments, the reimbursement of your COBRA Premiums (or Alternative Cash Payments), the Accelerated Vesting,  and all other consideration provided to you by the Company under Section 3 the Transition Agreement that you would not otherwise be entitled to receive (the “Release Consideration”), you agree to the terms below.
2.    General Release.  You hereby generally and completely release the Company and its parent or subsidiary entities, successors, predecessors and affiliates, and its and their directors, officers, employees, consultants, shareholders, agents, attorneys, insurers, affiliates and assigns (collectively, the “Released Parties”) of and from any and all claims, liabilities and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”).
3.    Scope of Release.  The Released Claims include, but are not limited to: (1) all claims arising from or in any way related to your employment with the Company, or the termination of that employment; (2) all claims related to your compensation or benefits from the Company (except as expressly provided in this Agreement), including but not limited to salary, bonuses, commissions, vacation pay, PTO, expense reimbursement, severance pay, fringe benefits, profit sharing, stock, stock options, or any other ownership or equity interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing, including but not limited to any claims arising under or based on your initial employment offer letter or subsequent Employment Agreement (including claims for severance benefits thereunder); (4) all tort claims, including but not limited to claims for battery, negligence, fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims in all jurisdictions, including but not limited to claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964, the federal Americans with Disabilities Act of 1990, the federal Family and Medical Leave Act, the Equal Pay Act of 1963, the Fair Labor Standards Act, the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act (together, the “ADEA”), the Employee Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act (and all similar state and local laws), the Iowa Civil Rights Act of 1965, the Iowa Wage Payment Collection Law, the Texas Commission on Human Rights Act, the Texas Payday Law, the Texas Labor Code, and any statute or regulation administered by the Texas Workforce Commission.
4.    Excluded Claims.  Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”):  (1) rights to apply for unemployment insurance benefits; (2) rights to workers’ compensation disability benefits, claims and payments, if applicable; 

-11-
 

(3) any rights or claims for indemnification pursuant to any written indemnification agreement with the Company to which you are a party, or under Company bylaws or articles, or under applicable law; (4) any rights which cannot be waived as a matter of law; or (5) any claims for breach of this Agreement.  You represent and warrant that, other than the Excluded Claims, you are not aware of any claims you have or may have against any of the Released Parties that are not included in the Released Claims.  You and the Company agree that the sole reason for the termination of your employment is a business reorganization which began occurring on or about the week of July 29, 2019.  All individuals who are being terminated in this business reorganization will be eligible for benefits based upon their execution of a release substantially similar to the Release Agreement.  You are acknowledging by signing this Agreement that you understand that you are eligible for the benefits which you will receive contingent upon your executing the Release Agreement, because you were part of this business reorganization.  A description of the employees on the Senior Executive Team that this business reorganization will affect is more fully set forth in Schedule A to the Release Agreement.  
5.    ADEA Waiver.  You further specifically agree that, as part of the Released Claims, you are releasing any claims that you could assert under the ADEA, as amended (the “ADEA Waiver”).  You acknowledge that: you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA; that the Release Consideration is being given in partial consideration for the ADEA Waiver; and that the Release Consideration is in addition to anything of value to which you were already entitled.  You further acknowledge that you have been advised, as required by the ADEA, that: (1) this ADEA Waiver does not apply to any rights or claims that arise after the date you sign this Agreement; (2) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (3) you have forty-five (45) days to consider this Agreement (although you may choose voluntarily to sign it earlier); (4) you have seven (7) days following the date you sign this Agreement to revoke the Agreement (in a written revocation provided to and received by the Company’s CEO within the 7-day revocation period); and (5) the Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement, provided that you have not timely revoked it (the “Effective Date”).  You understand and agree that, if you revoke the ADEA Waiver, you will not be entitled to the Release Consideration.
6.    Protected Rights.  Nothing in this Agreement shall prevent you from challenging the validity of the release of claims provided herein in a legal or administrative proceeding.  You further understand that nothing in this Agreement (including, without limitation, , Section 8 (Non-Disparagement) and Section 13 (Releases of Claims) above): limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”); prevents any party from providing information or disclosing the fact or terms of this Agreement as part of any government investigation: or prohibits any party from reporting possible violations of law or regulation to any Government Agencies or self-regulating entity under applicable law (including, but not limited to, the U.S. Securities and Exchange Commission’s Whistleblower Rule, of Section 21F of the U.S. Securities Exchange Act of 1934, as amended).  While this Agreement does not limit your right to receive an award for information 

-12-
 

provided to the Securities and Exchange Commission, you understand and agree that, to the maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any of the Released Claims and any rights you have waived by signing this Agreement.  
7.    Miscellaneous.  This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein and in the Transition Agreement, and it supersedes any other such promises, warranties or representations.  This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.  This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.  If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable.  This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Iowa as applied to contracts made and to be performed entirely within Iowa.

NEWLINK GENETICS CORPORATION

By: /s/ Bradley Powers    
Bradley Powers
Office of the CEO and General Counsel

    
Date

Nicholas Vahanian

/s/ Nicolas Vahanian    
Signature

    
Date

-13-
 

Exhibit 10.2

EXHIBIT B
Options and RSUs Subject to Twelve-Month Acceleration 
and Extended Exercise Period for Options
	
																									
	HOLDINGGROUP
	PARTICIPANTID
	HOLDINGID
	PLANSEC
	GRANTTYPE
	GRANTDATE
	NUMBEROFSHARES
	GRANTPRICE
	SHARESEXERCISED
	SHARESVESTED
	SHRSCANCWHTC
	OUTSTANDING
	OSEXERCISEABLERSDEFER
	CURRENTFMV
	FIRSTNAME
	LASTNAME
	ADDRESSLINE1
	ADDRESSLINE2
	CITY
	STATEORPROVINCECODE
	POSTALCODE
	COUNTRYCODE
	SHARESGRANTED
	AWARDTYPE
	MARKETPRICEATAWARD

	Options/SARs
	B13470133
	100204A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	22580
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	22580
	ISO
	1.77

	Options/SARs
	B13470133
	100204NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	167896
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	167896
	ISO
	1.77

	Options/SARs
	B13470133
	100205NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	95238
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	95238
	ISO
	1.77

	Options/SARs
	B13470133
	100326A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	7143
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	7143
	ISO
	1.77

	Options/SARs
	B13470133
	100326NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	14286
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	14286
	ISO
	1.77

	Options/SARs
	B13470133
	100503A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	8080
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	8080
	ISO
	1.77

	Options/SARs
	B13470133
	100503NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	31921
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	31921
	ISO
	1.77

	Options/SARs
	B13470133
	100684A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	3129
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	3129
	ISO
	1.77

	Options/SARs
	B13470133
	100684NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	26872
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	26872
	ISO
	1.77

	Options/SARs
	B13470133
	100719A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	1710
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	1710
	ISO
	1.77

	Options/SARs
	B13470133
	100719NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	22041
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	22041
	ISO
	1.77

	Options/SARs
	B13470133
	100947A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	813
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	813
	ISO
	1.77

	Options/SARs
	B13470133
	100947NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	19438
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	19438
	ISO
	1.77

	Options/SARs
	B13470133
	101042A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	190
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	190
	ISO
	1.77

	Options/SARs
	B13470133
	101042B
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	439
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	439
	ISO
	1.77

	Options/SARs
	B13470133
	101042NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	18246
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	18246
	ISO
	1.77

-14-
 

	
																									
	HOLDINGGROUP
	PARTICIPANTID
	HOLDINGID
	PLANSEC
	GRANTTYPE
	GRANTDATE
	NUMBEROFSHARES
	GRANTPRICE
	SHARESEXERCISED
	SHARESVESTED
	SHRSCANCWHTC
	OUTSTANDING
	OSEXERCISEABLERSDEFER
	CURRENTFMV
	FIRSTNAME
	LASTNAME
	ADDRESSLINE1
	ADDRESSLINE2
	CITY
	STATEORPROVINCECODE
	POSTALCODE
	COUNTRYCODE
	SHARESGRANTED
	AWARDTYPE
	MARKETPRICEATAWARD

	Options/SARs
	B13470133
	101042NB
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	2195
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	2195
	ISO
	1.77

	Options/SARs
	B13470133
	101381B
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	3477
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	3477
	ISO
	1.77

	Options/SARs
	B13470133
	101381NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	48828
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	48828
	ISO
	1.77

	Options/SARs
	B13470133
	101381NB
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	25820
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	25820
	ISO
	1.77

	Options/SARs
	B13470133
	101666
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	100000
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	100000
	ISO
	1.77

	Options/SARs
	B13470133
	800004A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	19532
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	19532
	ISO
	1.77

	Options/SARs
	B13470133
	800005A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	19532
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	19532
	ISO
	1.77

	Options/SARs
	B13470133
	800006A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	19531
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	19531
	ISO
	1.77

	Options/SARs
	B13470133
	800007A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	19531
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	19531
	ISO
	1.77

	Options/SARs
	B13470133
	800013-1B
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	6158
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	6158
	ISO
	1.77

	Options/SARs
	B13470133
	800013-1NA
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	10542
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	10542
	ISO
	1.77

	Options/SARs
	B13470133
	800013-1NB
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	14926
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	14926
	ISO
	1.77

	Options/SARs
	B13470133
	800013-2B
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	5269
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	5269
	ISO
	1.77

	Options/SARs
	B13470133
	800013-3B
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	5269
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	5269
	ISO
	1.77

	Options/SARs
	B13470133
	800013-4B
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	5275
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	5275
	ISO
	1.77

	Options/SARs
	B13470133
	800013-5B
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	7907
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	7907
	ISO
	1.77

	Options/SARs
	B13470133
	800013-6A
	2009 EQUITY INCENTIVE PLAN
	ISO
	7/31/2019
	 
	1.77
	0
	0
	0
	7907
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	7907
	ISO
	1.77

	Options/SARs
	B13470133
	800019-1
	2009 EQUITY INCENTIVE PLAN
	ISO
	3/1/2019
	 
	1.8
	0
	11562
	0
	92500
	11562
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	92500
	ISO
	1.8

	Options/SARs
	B13470133
	800019-2
	2009 EQUITY INCENTIVE PLAN
	PNQ
	3/1/2019
	 
	1.8
	0
	0
	0
	15430
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	15430
	PNQ
	1.8

	Options/SARs
	B13470133
	800019-3
	2009 EQUITY INCENTIVE PLAN
	PNQ
	3/1/2019
	 
	1.8
	0
	0
	0
	15410
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	15410
	PNQ
	1.8

-15-
 

	
																									
	HOLDINGGROUP
	PARTICIPANTID
	HOLDINGID
	PLANSEC
	GRANTTYPE
	GRANTDATE
	NUMBEROFSHARES
	GRANTPRICE
	SHARESEXERCISED
	SHARESVESTED
	SHRSCANCWHTC
	OUTSTANDING
	OSEXERCISEABLERSDEFER
	CURRENTFMV
	FIRSTNAME
	LASTNAME
	ADDRESSLINE1
	ADDRESSLINE2
	CITY
	STATEORPROVINCECODE
	POSTALCODE
	COUNTRYCODE
	SHARESGRANTED
	AWARDTYPE
	MARKETPRICEATAWARD

	Options/SARs
	B13470133
	800019-4
	2009 EQUITY INCENTIVE PLAN
	PNQ
	3/1/2019
	 
	1.8
	0
	0
	0
	15410
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	15410
	PNQ
	1.8

	Options/SARs
	B13470133
	800019-5
	2009 EQUITY INCENTIVE PLAN
	PNQ
	3/1/2019
	 
	1.8
	0
	0
	0
	23125
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	23125
	PNQ
	1.8

	Options/SARs
	B13470133
	800019-6
	2009 EQUITY INCENTIVE PLAN
	PNQ
	3/1/2019
	 
	1.8
	0
	0
	0
	23125
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	23125
	PNQ
	1.8

	RS Awards
	B13470133
	300011
	2009 EQUITY INCENTIVE PLAN
	RSU
	1/2/2014
	 
	 
	9500
	9500
	0
	0
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	9500
	RSU
	21.38

	RS Awards
	B13470133
	300024
	2009 EQUITY INCENTIVE PLAN
	RSU
	1/2/2014
	 
	 
	15000
	15000
	2675
	0
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	15000
	RSU
	21.38

	RS Awards
	B13470133
	300051
	2009 EQUITY INCENTIVE PLAN
	RSU
	1/2/2015
	 
	 
	25000
	25000
	6686
	0
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	25000
	RSU
	43.65

	RS Awards
	B13470133
	300075
	2009 EQUITY INCENTIVE PLAN
	RSU
	1/4/2016
	 
	 
	22092
	22092
	7370
	7364
	0
	FMV on 09/26/2019=$1.62
	Nicholas
	Vahanian
	1723 Glenleven Terrace
	 
	West Des Moines
	IA
	50266
	USA
	29456
	RSU
	34.73

-16-
 

Exhibit 10.2

EXHIBIT C
Proprietary Information Agreement
Incorporated by reference from  Exhibit A to Employment Agreement dated January 4, 2016, as filed with the Securities and Exchange Commission as Exhibit 10.32 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018

-17-
212332485 v1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]